Q3 2025 Earnings Call November 12, 2025 8:30 AM ESTCompany ParticipantsTal Jacobson - CEO & DirectorElad Tzubery - ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback